Absci Corp (ABSI) stock
ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
$7.58+0.11 (+1.40%)
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Absci r&d expenses
Research and development expenses are spending on new products and technology.
Absci's R&D Expenses for the twelve months ending Jun 30, 2026 was $86.49M, up 18.2% year over year. For fiscal 2025 it was $81.42M, up 27.5% from the year before. The highest annual figure on record is $81.42M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.42M | +27.5% |
| FY2024 | Dec 31, 2024 | $63.86M | +32.9% |
| FY2023 | Dec 31, 2023 | $48.07M | -18.4% |
| FY2022 | Dec 31, 2022 | $58.91M | +32.1% |
| FY2021 | Dec 31, 2021 | $44.59M | +289.5% |
| FY2020 | Dec 31, 2020 | $11.45M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.62M | +10.5% |
| Q1 FY2026 | Mar 31, 2026 | $19.28M | +17.8% |
| Q4 FY2025 | Dec 31, 2025 | $25.35M | +37.9% |
| Q3 FY2025 | Sep 30, 2025 | $19.25M | +7.0% |
| Q2 FY2025 | Jun 30, 2025 | $20.46M | +34.1% |
| Q1 FY2025 | Mar 31, 2025 | $16.36M | +33.7% |
| Q4 FY2024 | Dec 31, 2024 | $18.38M | +49.8% |
| Q3 FY2024 | Sep 30, 2024 | $17.99M | +63.1% |
| Q2 FY2024 | Jun 30, 2024 | $15.26M | +26.0% |
| Q1 FY2024 | Mar 31, 2024 | $12.24M | -3.3% |
| Q4 FY2023 | Dec 31, 2023 | $12.27M | +8.4% |
| Q3 FY2023 | Sep 30, 2023 | $11.03M | -29.0% |
| Q2 FY2023 | Jun 30, 2023 | $12.11M | -25.4% |
| Q1 FY2023 | Mar 31, 2023 | $12.66M | -20.0% |
| Q4 FY2022 | Dec 31, 2022 | $11.32M | -28.2% |
| Q3 FY2022 | Sep 30, 2022 | $15.53M | +44.7% |
| Q2 FY2022 | Jun 30, 2022 | $16.24M | +47.1% |
| Q1 FY2022 | Mar 31, 2022 | $15.83M | +124.5% |
| Q4 FY2021 | Dec 31, 2021 | $15.77M | +243.0% |
| Q3 FY2021 | Sep 30, 2021 | $10.73M | +298.6% |
| Q2 FY2021 | Jun 30, 2021 | $11.04M | +390.2% |
| Q1 FY2021 | Mar 31, 2021 | $7.05M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.60M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.69M | – |
| Q2 FY2020 | Jun 30, 2020 | $2.25M | – |
See a number that looks wrong?